{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:52:11Z","timestamp":1777575131183,"version":"3.51.4"},"reference-count":24,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Idiopathic mast cell activation syndrome (iMCAS) is a rare challenging diagnosis, and its treatment is not well standardized.  <jats:bold>Objective:<\/jats:bold> This study aimed to evaluate the clinical features of iMCAS and the potential need of omalizumab in clinical\n practice.  <jats:bold>Methods:<\/jats:bold> The clinical features and treatment regimens in 21 patients with iMCAS were evaluated. The number of anaphylaxis episodes, symptom severity scores via the visual analog scale (VAS), the disease control via the Likert scale were recorded at baseline, 6th-month\n and 1st-year visits.  <jats:bold>Results:<\/jats:bold> The affected organ systems were the skin (100%), respiratory (90%), cardiovascular (76.2%), and neurologic (40%). Nineteen patients (90.5%) experienced a grade V anaphylaxis and received adrenaline at baseline. The median (interquartile range\n [IQR]) serum tryptase level during an episode and at baseline were 11.7 ng\/mL (10.4\u201014.6 ng\/mL) and 5.29 ng\/mL (3.32\u20108.62 ng\/mL), respectively. Nineteen patients (90.5%) required omalizumab due to unresponsiveness to other treatments at a median (IQR) duration of 3 years (1\u20104\n years). By the end of 1 year, nine patients (47.4%) continued on 150 mg, seven patients (36.8%) continued on 300 mg, two patients (10.5%) continued on 450 mg, and one patient (5.2%) continued on 600 mg of omalizumab. Overall, the VAS scores significantly decreased at the 6th month and 1st\n year of omalizumab treatment compared to both the time of diagnosis (6th month vs. diagnosis: p\u2009=\u20090.001; 1st year vs. diagnosis: p\u2009=\u20090.012) and the initiation of omalizumab treatment (6th month vs. initiation: p\u2009=\u20090.001; 1st year vs. initiation: p\u2009=\u20090.001).\n The number of anaphylaxis episodes was significantly higher at the time of diagnosis compared with the 6th month (p\u2009=\u20090.001) and 1st year (p\u2009=\u20090.001) of omalizumab treatment and the number of anaphylaxis episodes at the initiation of omalizumab treatment was significantly\n higher compared with the 6th month of omalizumab treatment (p\u2009=\u20090.001) and the 1st year of omalizumab treatment (p\u2009=\u20090.001). Symptom control levels on the Likert scale at the 6th month and 1st year of omalizumab treatment were found to be significantly higher compared\n to both the time of diagnosis (6th month vs. diagnosis: p\u2009=\u20090.001; 1st year vs. diagnosis: p\u2009=\u20090.001) and the initiation of omalizumab treatment (6th month vs. initiation: p\u2009=\u20090.001; 1st year vs. initiation: p\u2009=\u20090.001).  <jats:bold>Conclusion:<\/jats:bold>\n The iMCAS causes severe anaphylaxis episodes that can be successfully prevented by omalizumab as an add-on treatment to other treatment options.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250025","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:34:02Z","timestamp":1751934842000},"page":"314-322","source":"Crossref","is-referenced-by-count":3,"title":["Idiopathic mast cell activation syndrome in real-life practice: clinical features and management"],"prefix":"10.2500","volume":"46","author":[{"given":"Merve","family":"Hormet Igde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pelin","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilkim Deniz","family":"Toprak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Eyice Karabacak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Semra","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Unal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asli","family":"Gelincik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.jaip.2021.06.011","article-title":"Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review","volume":"9","author":"G\u00fclen","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaip.2019.08.022","article-title":"Mast cell activation syndrome: tools for diagnosis and differential diagnosis","volume":"8","author":"Weiler","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","article-title":"Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management","volume":"94","author":"Pardanani","year":"2019","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2018.06.004","article-title":"Mast cell activation syndrome: importance of consensus criteria and call for research","volume":"142","author":"Valent","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM Consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.iac.2021.09.007","article-title":"Anaphylaxis and mast cell disorders","volume":"42","author":"Gulen","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.anai.2019.08.024","article-title":"Idiopathic anaphylaxis yardstick: practical recommendations for clinical practice","volume":"124","author":"Carter","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"B14","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World Allergy Organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jaip.2024.11.021","article-title":"The mastocytosis control test: a patient-reported outcome measure assessing disease control","volume":"13","author":"Siebenhaar","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jaip.2020.02.038","article-title":"Validation of the Angioedema Control Test (AECT)\u2014a patient-reported outcome instrument for assessing angioedema control","volume":"8","author":"Weller","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.4324\/9780203771587","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"key":"B20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.anai.2021.06.017","article-title":"Use of omalizumab for management of idiopathic anaphylaxis: a systematic review and retrospective case series","volume":"127","author":"Kaminsky","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaip.2023.11.041","article-title":"Low prevalence of idiopathic mast cell activation syndrome among 703 patients with suspected mast cell disorders","volume":"12","author":"Zaghmout","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2017.06.031","article-title":"Fatal anaphylaxis: mortality rate and risk factors","volume":"5","author":"Turner","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jaci.2007.09.022","article-title":"Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma","volume":"120","author":"Limb","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000504842","article-title":"Efficacy of omalizumab in mastocytosis: allusive indication obtained from a prospective, double-blind, multicenter study (XOLMA Study)","volume":"236","author":"Distler","year":"2020","journal-title":"Dermatology"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000004\/art00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T04:32:39Z","timestamp":1752553959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,1]]}},"alternative-id":["1088-5412(20250701)46:4L.314;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250025","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}